Habib Dable was appointed Director of SpyGlass Pharma, Inc. As of November 14, 2026, SpyGlass Pharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 9, 2026, naming 1 appointment (Form 8-K, February 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like SpyGlass Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
SpyGlass Pharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as SpyGlass Pharma, Inc. files it.
Also on the record for SpyGlass Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13D, by RA Capital Management, L.P. | 24.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Srinivas Akkaraju | 6.3% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D, by Gilde Healthcare Holding B.V. | 6.57% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D, by New Enterprise Associates 17, L.P. | 22.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by SANDS FRANK M. | 7.8% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13D, by Vensana Capital I GP, LLC | 9.9% of the class | 5%+ stakes | Source |
| February 6, 2026 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| January 29, 2026 | IPO filing, Form S-1/A | $15 to $17 a share | IPO filings | Source |
| January 16, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| June 5, 2025 | Form D, private offering | $75M sold | Form D page | Source |
Selling to them or working with them? See who runs SpyGlass Pharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on SpyGlass Pharma, Inc. and the records around it.
SpyGlass Pharma, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Gilde Healthcare Holding B.V. also filed stake reports on 2 other companies: Shoulder Innovations, Inc. (Aug 2026), Mobia Medical, Inc. (May 2026)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Watch SpyGlass Pharma, Inc.
Get an email when SpyGlass Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on SpyGlass Pharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on SpyGlass Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SpyGlass Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-09 | In | Director | 8-K, 2026-02-09 |
Who leads SpyGlass Pharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Habib Dable, appointed (filed 2026-02-09).
New leaders reset buying decisions — get the Full Report on SpyGlass Pharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at SpyGlass Pharma, Inc., with the record behind each one.
Find candidates like Director at SpyGlass Pharma, Inc.Every change, in the filing's words
Appointed: Habib Dable, Director
Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. (the "Company") on February 5, 2026 in connection with the Company's initial public offering (the "IPO").
- Mr. Dable will serve as a Class I director until a successor is duly elected and qualified or until an earlier resignation or removal.
- Mr. Dable will serve as a member of the compensation committee of the board of directors of the Company.
- Mr. Dable has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022.
- Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021.
- Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016.
- From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology Global Launch Team Head for EYLEA.
Tools for this story
Each opens in a new tab, filled in for SpyGlass Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
